Fasina O, Oluwasola O
Int Ophthalmol. 2017; 38(4):1747-1752.
PMID: 28626853
DOI: 10.1007/s10792-017-0612-5.
Kushnir I, Merimsky O
Oncol Lett. 2013; 5(2):424-426.
PMID: 23420786
PMC: 3573132.
DOI: 10.3892/ol.2012.1065.
Cahan L, Irie R, Singh R, Cassidenti A, Paulson J
Proc Natl Acad Sci U S A. 1982; 79(24):7629-33.
PMID: 6296843
PMC: 347401.
DOI: 10.1073/pnas.79.24.7629.
Bennett C, COOKE K
Br J Cancer. 1980; 41(5):734-44.
PMID: 6158965
PMC: 2010305.
DOI: 10.1038/bjc.1980.135.
Cantrell E
Br Med J. 1969; 2(5659):739-40.
PMID: 5786762
PMC: 1983541.
DOI: 10.1136/bmj.2.5659.739.
Immunity to malignant disease in man.
Fairley G
Br Med J. 1969; 2(5655):467-73.
PMID: 5771576
PMC: 1983396.
DOI: 10.1136/bmj.2.5655.467.
Malignant melanoma: the problem of lymph-node metastases.
Bodenham D
Proc R Soc Med. 1969; 62(11 Part 1):1090-2.
PMID: 5356855
PMC: 1810607.
Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy.
Morton D, Eilber F, JOSEPH W, Wood W, Trahan E, KETCHAM A
Ann Surg. 1970; 172(4):740-9.
PMID: 5272336
PMC: 1397284.
DOI: 10.1097/00000658-197010000-00018.
Transience of immune responses to tumour antigens in man.
Odili J, Taylor G
Br Med J. 1971; 4(5787):584-6.
PMID: 4943215
PMC: 1799950.
DOI: 10.1136/bmj.4.5787.584.
Evidence for antigenicity in human tumours with reference to both melanoma and acute leukaemia.
Fairley G
Br Med J. 1970; 4(5733):483-4.
PMID: 4921237
PMC: 1820087.
DOI: 10.1136/bmj.4.5733.483.
Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease.
Lewis M, Ikonopisov R, Nairn R, Phillips T, Fairley G, Bodenham D
Br Med J. 1969; 3(5670):547-52.
PMID: 4896110
PMC: 1984348.
DOI: 10.1136/bmj.3.5670.547.
Halo naevus--a frustrated malignant maelanoma.
Lewis M, COPEMAN P
Br Med J. 1972; 2(5804):47-8.
PMID: 4552592
PMC: 1789029.
DOI: 10.1136/bmj.2.5804.47-b.
Fluorescent antibody studies in malignant melanoma.
Whitehead R
Br J Cancer. 1973; 28(6):525-9.
PMID: 4205845
PMC: 2008930.
DOI: 10.1038/bjc.1973.182.
[Immunology of cancer].
Grundmann E
Langenbecks Arch Chir. 1971; 329:264-75.
PMID: 4144610
DOI: 10.1007/BF01770521.
Studies of humoral and cell-mediated immunity in human melanoma.
Mukherji B, NATHANSON L, Clark D
Yale J Biol Med. 1973; 46(5):681-92.
PMID: 4130586
PMC: 2591996.
Need for immunologic stimulators during immunosuppression produced by major cancer surgery.
COLE W, Humphrey L
Ann Surg. 1985; 202(1):9-20.
PMID: 3893336
PMC: 1250830.
DOI: 10.1097/00000658-198507000-00002.
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Carey T, Takahashi T, Resnick L, Oettgen H, Old L
Proc Natl Acad Sci U S A. 1976; 73(9):3278-82.
PMID: 1067619
PMC: 431008.
DOI: 10.1073/pnas.73.9.3278.
Stimulation of autologous blood lymphocytes by malignant lymphoma cells and homogenates.
Ludgate M, Gough J
Br J Cancer. 1976; 34(6):619-25.
PMID: 1008989
PMC: 2025238.
DOI: 10.1038/bjc.1976.222.
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
Shiku H, Takahashi T, Oettgen H
J Exp Med. 1976; 144(4):873-81.
PMID: 978138
PMC: 2190439.
DOI: 10.1084/jem.144.4.873.
Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.
Sherwin S, Sliski A, Todaro G
Proc Natl Acad Sci U S A. 1979; 76(3):1288-92.
PMID: 375235
PMC: 383236.
DOI: 10.1073/pnas.76.3.1288.
